Private equity firm TPG is exploring the sale of Lyric in a process that could value the healthcare software company at approximately $5 billion, according to sources close to the discussions cited by Reuters and KSL.com. The potential transaction highlights a broader recovery in software dealmaking following earlier sector-wide selloffs driven by artificial intelligence disruption fears.
The Bottom Line
The Valuation Math: Lyric currently generates about $250 million in annual EBITDA, placing its targeted $5 billion price tag at a 20x multiple.
The Backstory: TPG originally acquired the business—then known as ClaimsXten—for $2.2 billion in 2022 to clear antitrust hurdles for UnitedHealth’s acquisition of Change Healthcare.
The AI Factor: While TPG reports that Lyric has accelerated revenue growth through AI deployment, prospective buyers are still weighing whether cheaper AI-native competitors could disrupt the claims-management space.
Tracing Lyric’s Path From Change Healthcare to a Multibillion-Dollar Valuation
The roots of this potential multi-billion dollar sale stretch back to a major antitrust maneuver. In 2022, private equity titan TPG purchased ClaimsXten for roughly $2.2 billion. The asset had previously been housed inside Change Healthcare. To smooth potential regulatory hurdles threatening UnitedHealth’s massive $13 billion acquisition of Change, the software division was spun off. TPG subsequently rebranded the entity as Lyric the following year.
Here is the kicker: that strategic carve-out has blossomed into a heavy-hitting financial asset. According to insiders speaking with Reuters, Lyric now generates roughly $250 million in annual earnings before interest, taxes, depreciation, and amortization (EBITDA). Apply a standard 20 times multiple to that cash flow, and you quickly arrive at the $5 billion valuation figure currently being floated in private markets.
To shepherd the potential sale, TPG has enlisted investment bankers at JPMorgan Chase. However, sources familiar with the matter emphasize that these deliberations remain private and fluid. There is zero guarantee that the exploration will culminate in a finalized transaction, and both TPG and JPMorgan Chase declined to comment when approached by reporters. Lyric also did not immediately respond to requests for comment.
Navigating the AI Disruption Anxiety in Enterprise Software
The timing of TPG’s exploratory sale is hardly accidental. Software dealmaking is clawing its way back after an intense period of market jitters earlier this year, when Wall Street panicked over the threat of rapid artificial intelligence disruption across the entire software sector.
Even highly specialized B2B software providers face tough questions about their long-term moats. Major health insurers—including industry heavyweights like UnitedHealth, CVS, and Humana—rely on Lyric’s specialized platform to meticulously identify and prevent inaccurate medical claims payments. It is high-stakes, data-heavy infrastructure.
TPG has maintained that Lyric has directly benefited from deploying artificial intelligence, noting that its vast proprietary datasets allow it to compound those technological advantages. But potential buyers are looking further down the road. Some prospective acquirers are actively assessing whether nimble, AI-native startups could eventually replicate these payment-integrity and claims-management functions at a fraction of the cost. If true, that shift could fundamentally undermine the financial assumptions underpinning legacy software valuations.
Market Realities and Public Peer Sentiment
The underlying tension between legacy software utility and AI-native disruption isn’t just theoretical speculation; it is visible in public market volatility. Investors need look no further than smaller public peer Claritev to gauge sector sentiment. Between September 2025 and May of this year, Claritev’s stock suffered a brutal 80% tumble as market participants fretted over the impact of AI on specialized software providers.
While Claritev’s stock has recovered some ground since those lows, it continues to trade below $38 per share—a steep drop from the $72 price tag it commanded just one year ago. That kind of public market turbulence inevitably casts a long shadow over private equity exit strategies, forcing firms like TPG to carefully test market appetite before committing to a formal auction process.
| Metric / Event | Details |
|---|---|
| Target Valuation | Approximately $5 billion |
| Estimated Annual EBITDA | About $250 million |
| Implied EBITDA Multiple | Roughly 20x |
| Initial Acquisition Price (2022) | Roughly $2.2 billion (as ClaimsXten) |
| Advising Investment Bank | JPMorgan Chase |
As the private equity landscape watches to see if TPG moves forward with a formal sale process, the broader enterprise software sector hangs in the balance. Whether a $5 billion price tag can be secured in an era of rapid technological evolution will serve as a definitive stress test for specialized business-to-business tech assets.
Drop a comment below: Do you think legacy enterprise software can successfully fend off agile AI-native upstarts, or are multibillion-dollar valuations facing an inevitable correction?
